iBio (IBIO) Operating Income (2010 - 2026)
iBio (IBIO) posted quarterly Operating Income of -$8.4 million for Q1 2026, down 71.45% year-over-year from -$29.3 million in Q1 2025, and up 11.43% quarter-over-quarter from -$9.4 million in Q4 2025.
iBio (IBIO) Operating Income (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Operating Income for 17 consecutive years, with -$8.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 71.45% year-over-year to -$8.4 million; the TTM figure through Mar 2026 stood at -$29.0 million (down 72.24% YoY), while the FY2025 annual figure was -$18.6 million, down 11.83% from the prior year.
- Operating Income improved to -$8.4 million in Q1 2026 per IBIO's latest filing, from -$9.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$3.4 million in Q2 2024 and bottomed at -$10.6 million in Q4 2022.
- Historically, Operating Income has averaged -$6.2 million across 5 years, with a median of -$5.2 million in 2025.
- Annual changes were most pronounced in 2023 — Operating Income soared 57.48% — and 2025, when it tumbled 113.74%.
- iBio's Operating Income stood at -$10.6 million in 2022, then jumped by 57.48% to -$4.5 million in 2023, then increased by 1.71% to -$4.4 million in 2024, then slumped by 113.74% to -$9.4 million in 2025, then grew by 11.43% to -$8.4 million in 2026.
- Business Quant data shows IBIO's Operating Income at -$8.4 million in Q1 2026, -$9.4 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | iBio | 172.82 Mn | 172.82 Mn | - | -8.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.37 Mn |
| Dec 31, 2025 | -9.45 Mn |
| Sep 30, 2025 | -5.95 Mn |
| Jun 30, 2025 | -5.20 Mn |
| Mar 31, 2025 | -4.88 Mn |
| Dec 31, 2024 | -4.42 Mn |
| Sep 30, 2024 | -4.11 Mn |
| Jun 30, 2024 | -3.41 Mn |
| Mar 31, 2024 | -3.63 Mn |
| Dec 31, 2023 | -4.50 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -4.97 Mn |
| Mar 31, 2023 | -6.17 Mn |
| Dec 31, 2022 | -10.57 Mn |
| Sep 30, 2022 | -7.64 Mn |
| Jun 30, 2022 | -10.45 Mn |
| Mar 31, 2022 | -6.79 Mn |
| Dec 31, 2021 | -7.23 Mn |
| Sep 30, 2021 | -5.23 Mn |
| Jun 30, 2021 | -9.44 Mn |